ArticleIranian journal of pharmaceutical research : IJPR
Design, Expression, and Binding Interactions Study of the Recombinant Engineered IL-6R.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The trans-signaling pathway mediated by soluble interleukin-6 receptor (IL-6R) plays a crucial role in the pathogenesis of chronic inflammatory diseases, autoimmune disorders, and various cancers. Objectives: The present study aimed to model amino acid residues 121 to 300 of the IL-6R and to predict the effect of this selected fragment on reducing its interaction with glycoprotein 130 (gp130) using molecular docking. Methods: The engineered selected sequence interleukin-6 receptor (seIL-6R) was designed to diminish interaction with gp130. Physicochemical parameters were evaluated using the ProtParam tool. Structural modeling and prediction were performed using AlphaFold. Molecular docking was conducted using ClusPro. Subsequently, the seIL-6R gene was recombinantly expressed in the Chinese hamster ovary (CHO)-K1 cell line. The expression of recombinant seIL-6R was evaluated by Western blotting, and its secondary structure was examined by Fourier transform infrared (FTIR) spectroscopy. Results: Evaluation of the physicochemical parameters of the recombinant seIL-6R protein demonstrated improved stability and solubility, along with a reduced molecular weight (20.6 kDa). Molecular docking results indicated reduced binding of seIL-6R to gp130. Expression of the recombinant seIL-6R protein was confirmed by Western blotting. Furthermore, FTIR spectroscopy revealed that the secondary structure of seIL-6R was preserved and consistent with predicted structural models. Conclusions: This engineered protein has potential for further investigation as a promising and cost-effective therapeutic agent targeting IL-6-related pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.